Cystic Fibrosis Therapeutics Market Size & Share 2026-2035

Cystic Fibrosis Therapeutics Market Size

The cystic fibrosis therapeutics market was valued at USD 18.1 billion in 2025. The market is expected to grow from USD 20.9 billion in 2026 to USD 79.7 billion in 2035, growing at a CAGR of 16%, according to the latest report published by Global Market Insights, Inc.

The rising prevalence of cystic fibrosis (CF) and growing emphasis on effective treatment has driven market growth. The high prevalence of CF cases results in the need for early detection and improved diagnostic solutions which in turn stimulates the adoption of effective therapeutics in the market. According to a study reported in the Journal of Cystic Fibrosis, nearly 65% of CF cases were diagnosed with approximately 105,352 cases across 94 countries in 2022. These growing CF incidences emphasize the need for effective treatment to enhance the management of the condition. This growth in healthcare services drives the demand for emerging therapeutics, thereby bolstering market growth.

Furthermore, increased R&D funding accelerates research activities, driving advancements in potential treatments, resulting in further growth of the market. For example, the emergence of CF transmembrane conductance regulator (CFTR) modulators and the expanding pipeline, with a growing number of clinical trials to develop potential therapies addressing the growing CF burden further expanded opportunities in the market.

For instance, in September 2024, an investigational Phase 1b study was initiated by ReCode Therapeutics. This study aimed to evaluate the tolerability and safety of RCT2100, an inhaled mRNA therapy, in CF patients who are unable to respond to CFTR modulators and RCT1100 for the treatment of primary ciliary dyskinesia. This study initiation and expected positive results are likely to offer significant opportunities for a potential treatment line in CF patients. Also, an increase in awareness of advanced therapies fuels the adoption of the therapeutics, thus stimulating market growth.

The market witnessed considerable growth between 2022 and 2024, growing from USD 11.3 billion in 2022 to USD 15.7 billion in 2024, primarily due to the increasing adoption of highly effective CFTR modulator therapies, particularly those developed by Vertex Pharmaceuticals such as Trikafta (also marketed as Kaftrio), which target the underlying genetic cause of cystic fibrosis and significantly improve patient outcomes. In addition, improved newborn screening programs and earlier diagnosis led to higher treatment uptake during this period, while the high annual cost of advanced therapies contributed to overall market value growth.

Cystic fibrosis therapeutics refers to the treatment developed to address and improve the symptoms caused by CF. This genetic disorder primarily affects the digestive, respiratory, and reproductive systems. The treatment methods include medication including CFTR modulators, mucolytic agents, bronchodilators, anti-infective agents, and other drug classes while non-medication management includes therapeutic interventions to manage the CF symptoms. 

Key players such as Vertex Pharmaceuticals, Gilead, F. Hoffmann-La Roche, Novartis, and Chiesi Farmaceutici are driving the market growth through continuous research and development of innovative therapies, expanding CFTR modulator indications to cover more genetic mutations and age groups, and strategic collaborations with healthcare providers to enhance treatment accessibility.

Cystic Fibrosis Therapeutics Market Trends

The global cystic fibrosis treatment market is experiencing growth due to several market trends that are creating new opportunities for innovative therapies, improved patient outcomes, and expanded treatment accessibility for individuals affected by cystic fibrosis.

• Improvements in the CFTR modulator therapy coupled with emerging advanced therapies to address the concerns of CF patients are a key trend fueling the growth of the cystic fibrosis therapeutics industry.
• Additionally, the development of combination therapies or other CFTR modulators such as Trikafta, Symdeko, and Orkambi have significantly improved lung function and reduced hospitalizations among CF patients.
• These therapies primarily target the underlying cause of cystic fibrosis, managing pulmonary complications and enhancing lung function and improving life expectancy.
• For example, in December 2020 Vertex Pharmaceuticals received approval from the Food and Drug Administration (FDA) for TRIKAFTA in CF patients of 2 years of age and older having one F508del mutation or other responsive mutations. This approval expanded treatment access to an estimated additional 300 patients. This achievement highlighted the ongoing determination to improve care delivery for patients with CF.
• Further, the growing advancements in CF treatment with a focus on developing potential breakthroughs that offer long-term solutions for CF patients has further fueled market growth. In addition, to address these concerns, key companies are heavily investing in R&D, broadening pipeline studies to enhance disease management and improve patient outcomes.
• For instance, an innovative treatment developed in Western Australia for cystic fibrosis patients is undergoing clinical trials in the U.S. and Australia. The Kids Research Institute Australia and Perth Children's Hospital stated the treatment RSP-1502, combines the use of an inhaled antibiotic booster for the treatment of respiratory infections in CF patients. However, an early WA-based trial utilizing this inhaled antibiotic booster in chronically infected CF patients showcased a staggering 800-fold reduction in bacterial load and a lung function improvement of 16% on average compared to the 5% improvement noted with standard treatment. Therefore, this new combination represents an advancement in improving anti-infective outcomes and lung function in CF patients and thereby driving the market growth.

Cystic Fibrosis Therapeutics Market Analysis

Based on type, the global cystic fibrosis therapeutics market is categorized into medication and non-medication. The medication segment dominated the global market and was valued at USD 16.2 billion in 2025.

• The medication segment is further categorized into CFTR modulators, mucolytic agents, bronchodilators, anti-infective agents, pancreatic enzyme supplements, and other drug classes.
• The growing advancements in drug therapies including CFTR modulators and other symptomatic treatments have significantly prompted the demand for medication, thereby leading to segment prominence in the market.
• As these drugs tend to improve the patient outcome responses by targeting CF symptoms and genetic mutations.
• However, the increased frequency of CF cases bolstered R&D funding and activities enabling the availability of potential treatments, strengthening the segment position in the market.
• Furthermore, advancements in personalized medicine and expanding reimbursement support, emphasizing its central role in improving the health of CF patients, are anticipated to drive market growth in the coming years.
• On the other hand, the non-medication segment is expected to grow at 14.7% CAGR during the forecast period due to the increasing emphasis on comprehensive management of cystic fibrosis beyond pharmacological treatment.
• Rising awareness about long-term disease management, improvements in home-based care technologies, and growing adoption of digital monitoring tools and respiratory support systems are further encouraging the use of non-drug therapeutic approaches, thereby contributing to the strong growth of this segment.

Based on the age group, the global cystic fibrosis therapeutics market is categorized into Below 18 years, 18 - 40 years, and 41 and above. The below 18 years segment accounted for the highest market share of 76.9% in 2025.

• The segment prominence below 18 age group was asserted to be the high occurrence of diseases such as CF in children and adolescents.
• Such diseases have a low age of onset prompting early diagnosis and treatment, thus surging the need for focused therapies and individualized care in this population.
• In addition, increased attention from caregivers, better diagnostics, and access to new treatment options also play a role in the prominence of this segment.
• Further, the emphasis on pediatric research and regulatory approvals sustain dominance in the market throughout the forecast period.

North America Cystic Fibrosis Therapeutics Market

North America dominated the global cystic fibrosis therapeutics industry with a market share of 74.5% in 2025.

• North America dominated the market due to the presence of major pharmaceutical companies resulting in widespread availability and accessibility to advanced treatment options.

• Additionally, strong reimbursement policies and insurance coverage enable patients to access expensive cystic fibrosis treatments more easily.
• The region further benefits from well-established newborn screening programs and active research support from organizations such as the Cystic Fibrosis Foundation, which continue to drive treatment adoption and innovation.

In 2025, the U.S. held a prominent position in the North America cystic fibrosis therapeutics market accounting for USD 12.1 billion.

• The high prevalence of CF in the country elevated the need for effective CF treatment coupled with rigorous R&D activities aimed at managing the disease burden, has strengthened U.S. leadership in the market.
• According to the American Lung Association, nearly 40,000 children and adults are living with CF which is up from 38,804 prevalent cases in 2020 in the U.S. These rising cases are surging the demand for effective treatment solutions and subsequently boost market growth in the U.S.
• In addition, the country gains higher traction in the market through extensive government and private funding contributions in developing innovative therapies and advanced drugs like CFTR modulators to enhance the management of CF symptoms.
• Moreover, the presence of organizations such as Cystic Fibrosis Foundation and its support programs and reimbursement initiatives also contributes to the high adoption of treatments.
• Furthermore, the presence of top pharmaceutical companies along with significant investment in R&D continues to strengthen the position of the country in the region.

Europe Cystic Fibrosis Therapeutics Market

The Europe cystic fibrosis therapeutics industry was valued at USD 3.6 billion in 2025 and is expected to reach USD 15.5 billion by 2035.

• The Europe cystic fibrosis therapeutics industry is growing due to the increasing number of specialized treatment centers for Cystic Fibrosis, which improve patient access to comprehensive care and advanced therapies.
• The region also benefits from strong clinical research activity and participation in international clinical trials, enabling faster evaluation and adoption of new treatments.
• In addition, greater awareness among healthcare professionals and patients is supporting earlier treatment initiation.
• The market is further supported by the expansion of treatment availability through regional pharmaceutical companies, which continue to introduce advanced therapies across European countries.

Germany is poised to grow at a substantial growth rate in the Europe cystic fibrosis therapeutics market.

• The market growth potential in the country is attributed to the rising CF incidence along with the growing awareness and improved management in CF management.
• In addition, the increased focus and efforts towards early detection through newborn screening programs offered in the country stimulates demand for effective treatment options.
• For instance, every year, the NBS center Heidelberg screens about 140,000 newborns from Southwest Germany. Almost all parents opting for NBS for their children also consented to partake in CF-NBS (99.8%). This initiative enhances early intervention, improving patient outcomes, urging the R&D investments, and expansion of treatment accessibility in CF patients.
• Moreover, the substantial investments in R&D and collaboration between research and academic institutes and the pharmaceutical companies promote the development of innovative therapies. For example, Mukoviszidose e.V. provides funding for CF-related research projects and clinical studies entailing a clinical application in CF care and awareness. This supportive funding aims to optimize R&D activities corresponding to the disease burden and improve patient outcomes with an emerging opportunity.
• Moreover, the supportive reimbursement policies and public aid for rare disease awareness and treatment further strengthened Germany’s position within the European market.

Asia Pacific Cystic Fibrosis Therapeutics Market

Asia Pacific cystic fibrosis therapeutics industry is expected to witness growth at 16.5% CAGR over the analysis period.

• The growth is driven by improving diagnostic capabilities and increasing awareness of Cystic Fibrosis in several countries across the region.

• Rising healthcare expenditure and the gradual expansion of access to advanced therapies are also supporting market growth.
• In addition, increasing presence of global pharmaceutical companies such as Vertex Pharmaceuticals and Novartis in the Asia Pacific region is contributing to the wider availability of cystic fibrosis treatments, further accelerating market development.

Japan held the prominent position in the Asia Pacific cystic fibrosis therapeutics industry.

• The country's market was driven by the increasing focus on rare disease treatment coupled with favorable regulatory support like the Orphan Drug Designation system, fostering innovation in CF drug development in the country
• In addition, the growing awareness and treatment accessibility has improved due to the expansion of early diagnosis programs, and the advancement of genetic screening has strengthened Japan's position in the Asia Pacific market.
• Therefore, these factors collectively help maintain Japan’s position expanding CF treatment availability in the region and improve market growth.

Latin America Cystic Fibrosis Therapeutics Market

Brazil's cystic fibrosis therapeutics industry is projected to witness growth in the Latin America market.

• The Brazilian market is set for substantial growth due to significant CF patient population emphasizing the need for potential CF treatment with improved efficacy.

• For instance, according to the Brazilian cystic fibrosis Patient Registry, Brazil had an incidence rate of about 1 in 7,576 live births with cystic fibrosis in 2017. Additionally, newborn screening for CF is mandatory, aiding early diagnosis and intervention. Therefore, the rising CF cases with expanding screening access would likely spur the demand for potential disease management solutions thereby propelling the market growth.
• Furthermore, rising awareness, advancements in healthcare infrastructure, improved access to advanced treatments and rising investments in rare disease research further positions Brazil as a key market for cystic fibrosis therapeutics in Latin America.

Middle East and Africa Cystic Fibrosis Therapeutics Market

Saudi Arabia is anticipated to grow at a substantial growth rate in the Middle East and Africa cystic fibrosis therapeutics industry.

• Saudi Arabia is poised for growth driven by several factors such as the increasing prevalence of CF, combined with rising awareness and improved healthcare infrastructure spurring the demand for effective treatments.

• In addition, the government initiatives and support enhance healthcare access and R&D activities further stimulate market growth.
• Additionally, the expansion of innovative therapies like gene therapy and CFTR modulators is expected to expand treatment options. Therefore, these factors highlight Saudi Arabia’s potential in the Middle East and African cystic fibrosis therapeutics industry.

Cystic Fibrosis Therapeutics Market Share

The top 4 players in the global cystic fibrosis therapeutics industry hold a share of ~67.4%. The key players in the market such as Vertex Pharmaceuticals, F. Hoffmann-La Roche, Gilead, and Novartis hold a substantial share of the industry. These companies are actively focusing on developing potential treatment options, targeting the disease's underlying genetic causes, addressing CF management. In addition, to address the needs, companies are actively engaging in market consolidation activities, including collaborations with research institutions and healthcare organizations to promote innovation and expedite drug discovery.

The cystic fibrosis therapeutics market is highly competitive, driven by continuous innovation, robust research and development activities, and the introduction of advanced therapies. Furthermore, the extended pipeline for CF therapeutics, including novel drugs undergoing clinical trials, highlighted the growing focus to address unmet needs. Also, the increasing number of approvals and the growing focus on personalized medicine intensify the competition in the market. Companies are heavily investing to expand their geographic presence, particularly in emerging markets, to capitalize on growing demand and improve accessibility to cutting-edge treatments and increase market penetration.

Cystic Fibrosis Therapeutics Market Companies

Prominent players operating in the cystic fibrosis therapeutics industry are as mentioned below:

• Alcresta Therapeutics

• Baxter 
• Chiesi Farmaceutici
• F. Hoffmann-La Roche
• Gilead
• Koninklijke Philips
• Lupin
• Monaghan Medical 
• Novartis
• Savara
• Sionna Therapeutics
• Teva Pharmaceutical Industries
• Vertex Pharmaceuticals 
• Vertex Pharmaceuticals- Vertex Pharmaceuticals is a key leader in the cystic fibrosis therapeutics market with a 35.6% share, focusing on CFTR modulators to improve patient outcomes and life expectancy. The company has a strong pipeline, including VX-522, a CFTR mRNA therapy delivered via lipid nanoparticles, designed to target the underlying cause of CF lung disease. This investigational therapy could provide an innovative alternative for patients who do not respond to current CFTR modulators.
• Gilead- Gilead is a leading provider of cystic fibrosis-specific antibacterial and antifungal therapies, focusing on controlling chronic lung infections that are common in patients with cystic fibrosis. Its treatments aim to reduce infection-related complications, enhance patient safety, and improve overall treatment outcomes. By addressing one of the most critical aspects of CF care, Gilead contributes significantly to better quality of life and long-term health for patients.
• F. Hoffmann-La Roche- F. Hoffmann-La Roche focuses on providing disease-modifying therapies to cater to the needs of CF patients, leveraging expertise in precision medicine and diagnostics. For instance, Roche acquired the phase-1 pan-genotype CF program from Enterprise Therapeutics, providing a set of potentiator compounds TMEM16A designed to restore lung function in CF patients. This acquisition aimed at expanding the company’s research capabilities, accelerating innovation in the CF industry.

Cystic Fibrosis Therapeutics Industry News

• In October 2025, Vertex Pharmaceuticals presented multiple abstracts at the North American Cystic Fibrosis Conference (NACFC), held from October 22–25 in Seattle, Washington, highlighting the clinical benefits of CFTR modulators, including its most recently approved therapy, ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor). This presentation reinforced the company’s leadership in CF treatment and is expected to boost physician awareness and adoption of its therapies, strengthening market position and driving revenue growth.
• In December 2024, Vertex Pharmaceuticals received FDA approval for ALYFTREK, a once-daily triple combination CFTR modulator, for CF patients aged 6 and older with at least one F508del mutation or another responsive CFTR mutation. This approval marked a significant advancement in CF treatment options, enhancing patient care and outcomes.
• In October 2024, Researchers at the University of Liverpool initiated a strategy to improve lung health management in the UK by introducing a Cystic Fibrosis Innovation Hub. The hub was funded by LifeArc and Cystic Fibrosis Trust to enhance tests and treatments efficacy for lung infections in CF patients.
• In January 2024, Lupin received a U.S. FDA tentative approval to market its generic Ivacaftor oral granules for CF treatment. This approval marked a significant milestone for Lupin to penetrate in market and offer effective therapies catering to CF patient needs.

The cystic fibrosis therapeutics market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Medication
  • By drug class
    • CFTR modulators
    • Mucolytic agents
    • Bronchodilators
    • Anti-infective agents
    • Pancreatic enzyme supplements
    • Other drug classes
  • By route of administration      
    • Oral
    • Inhalation
  • By distribution channel 
    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies
• Non-medication

Market, By Age Group

• Below 18 years
• 18 - 40 years
• 41 and above

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Ireland
  • Denmark
• Asia Pacific
  • India
  • Japan
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE